Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 46

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 46
---
108,969 shares of common stock that may be acquired by Mr. Aziz pursuant to the exercise of stock options within 60 days of March 24, 2025 and (iiI) the shares described in footnote (2) above, of which Mr. Aziz disclaims beneficial ownership of all such shares except to the extent of his pecuniary interests therein.

Consists of 110,070 shares of common stock that may be acquired by Ms. FitzPatrick pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 31,802 shares of common stock and (ii) 109,272 shares of common stock that may be acquired by Dr. Marks pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 3,166 shares of common stock and (ii) 123,606 shares of common stock that may be acquired by Ms. Martin pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 9,077 shares of common stock and (ii) 108,969 shares of common stock that may be acquired by Dr. Readnour pursuant to the exercise of stock options within 60 days of March 24, 2025, (iii) 652,573 shares of common stock held by MGC Venture Partners QP 2018, LP (“MGC 2018 QP”), and (iv) 582,288 shares of common stock held by MGC Venture Partners 2018, LP (“MGC 2018 LP”). MGC Venture Partners 2018 GP, LLC (“MGC 2018 GP”) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. Dr. Readnour is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. Dr. Readnour, however, disclaims beneficial ownership of such shares of common stock, except to the extent of any pecuniary interest